CT-guided 125I brachytherapy for recurrent ovarian cancer

被引：6

作者：

Liu, Ping ^{[1
]}

Tong, Lina ^{[1
]}

Huo, Bin ^{[2
]}

Dai, Dong ^{[3
]}

Liu, Wenxin ^{[4
]}

Wang, Ke ^{[4
]}

Wang, Ying ^{[1
]}

Guo, Zhi ^{[1
]}

Ni, Hong ^{[1
]}

机构：

[1] Tianjin Med Univ Canc Inst & Hosp, Dept Intervent Therapy, Natl Clin Res Ctr Canc, Key Lab Canc Prevent & Therapy, Tianjin, Peoples R China

[2] Tianjin Med Univ, Hosp 2, Dept Oncol, Tianjin, Peoples R China

[3] Tianjin Med Univ Canc Inst & Hosp, Dept Mol Imaging & Nucl Med, Tianjin, Peoples R China

[4] Tianjin Med Univ Canc Inst & Hosp, Dept Gynecol Oncol, Tianjin, Peoples R China

来源：

ONCOTARGET | 2017年 / 8卷 / 35期

关键词：

I-125; seeds; brachytherapy; recurrent ovarian cancer; BEAM RADIATION-THERAPY; INTERSTITIAL BRACHYTHERAPY; CYTOREDUCTIVE SURGERY; CARCINOMA; RECOMMENDATIONS; MALIGNANCIES; RADIOTHERAPY; MANAGEMENT; DOSIMETRY; TOXICITY;

D O I：

10.18632/oncotarget.15905

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

This retrospective study was to evaluate the local control and survival of I-125 brachytherapy for recurrent ovarian cancer. 52 I-125 brachytherapy procedures were performed in 47 patients with 51 recurrent ovarian cancer lesions. The follow-up period was 1-55 months (median 12 months). The local control rate (LC) of 3, 6, 12, 24 and 36 months was 93.3%, 77.7%, 58.9%, 38.7% and 19.3%, respectively. Patients with tumor size = 4cm (85.7% vs 40.0%, P = 0.037) and actual D90 between 110 to 130Gy (47.4% vs 66.7% vs 62.5%, P = 0.029) had better LC. The 1, 2 and 3 years of overall survival (OS) was 79.3%, 63.0% and 52.5%, respectively. The poor performance status (HR 3.821, 95% CI 1.383-10.555; P = 0.010), concurrent distant metastasis (HR 9.222, 95% CI 1.710-49.737; P = 0.010) and large postoperative residual tumor size (HR 6.157, 95% CI 1.438-26.367; P = 0.014) were closely correlated with a poor OS. Our data indicate that CT-guided I-125 brachytherapy is an effective and safe modality for the local treatment of recurrent ovarian cancer.

引用

页码：59766 / 59776

页数：11

共 40 条

[1]

[Anonymous], RADIOLOGY

[2]

[Anonymous], BIOMED RES INT

[3] Intraoperative radiation therapy (IORT) for gynecologic malignancies [J].

Backes, Flood J. ;

Martin, Douglas D. .

GYNECOLOGIC ONCOLOGY, 2015, 138 (02) :449-456

[4]

BRADY LW, 1995, CANCER, V76, P2143, DOI 10.1002/1097-0142(19951115)76:10+<2143::AID-CNCR2820761339>3.0.CO

[5]

2-4

[6] Prognostic factors for patients treated for a recurrent FIGO stage III ovarian cancer: A retrospective study of 108 cases [J].

Classe, J. M. ;

Jaffre, I. ;

Frenel, J. S. ;

Bordes, V. ;

Dejode, M. ;

Dravet, F. ;

Ferron, G. ;

Marchal, F. ;

Rigaud, D. Berton ;

Loussouarn, D. ;

Campion, L. .

EJSO, 2011, 37 (11) :971-977

[7] TOXICITY CRITERIA OF THE RADIATION-THERAPY ONCOLOGY GROUP (RTOG) AND THE EUROPEAN-ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER (EORTC) [J].

COX, JD ;

STETZ, J ;

PAJAK, TF .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1995, 31 (05) :1341-1346

[8] Sensitivity of human prostatic carcinoma cell lines to low dose rate radiation exposure [J].

Deweese, TL ;

Shipman, JM ;

Dillehay, LE ;

Nelson, WG .

JOURNAL OF UROLOGY, 1998, 159 (02) :591-598

[9]

Eisenkop SM, 2000, CANCER, V88, P144, DOI 10.1002/(SICI)1097-0142(20000101)88:1<144::AID-CNCR20>3.0.CO

[10]

2-X

← 1 2 3 4 →